Jeff Sharman's guest appearances

Jeff Sharman

Hematologic Oncology Update

Cancer Conference Update

Research To Practice | Oncology Videos

Plenary Session

Oncology Today with Dr Neil Love

Myeloproliferative Neoplasms

Brad S Kahl

Craig Moskowitz

Irene M Ghobrial

Noopur Raje

Ross Camidge

Rafael Fonseca

Benjamin Levy

Jennifer Woyach

Christopher Flowers

Ola Landgren

Alexander Perl

Susan M O’Brien

Rami Komrokji

Mikkael A Sekeres

OwlTail

Oncology Grand Rounds Series: Part 4 — Faculty Presentation 2: New agents and regimens for CLL in the front-line and relapsed/refractory settings — Dr Sharman CNE information and select publications

Oncology Grand Rounds Series: Part 4 — Faculty Presentation 2: New agents and regimens for CLL in the front-line and relapsed/refractory settings — Dr Sharman <a href="http://m.researchtopractice.com/ONSCLL2020/Presentations" rel="nofollow" target="_blank">CNE information and select publications</a>

Chronic Lymphocytic Leukemia | Jeff Sharman, MD

Dr Jeff Sharman from the Willamette Valley Cancer Institute and Research Center discusses clinical trials evaluating the use of Bruton tyrosine kinase inhibitors as treatment for patients with SARS-CoV-2. Additional Resources   Roschewski M et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunol 2019;5(48):eabd0110. Abstract  AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 [press release]. April 14, 2020. Chong EA et al. BTK inhibitors in cancer patients with COVID19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte). Clin Cancer Res 2020;[Published OnlineFirst]. Abstract COVID-19 and CLL: Frequently Asked Questions. Hematology.org. May 6, 2020;Version 1.3. Mehta P et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229);1033-4. Correspondence Koffman B et al. Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol 2020;[Epub ahead of print]. Correspondence Treon ST et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood 2020;135(21):1912–5. Full text

Dr Jeff Sharman from the Willamette Valley Cancer Institute and Research Center discusses clinical trials evaluating the use of Bruton tyrosine kinase inhibitors as treatment for patients with SARS-CoV-2. Additional Resources <ul> <li> Roschewski M et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunol 2019;5(48):eabd0110. <a href="https://immunology.sciencemag.org/content/5/48/eabd0110" rel="nofollow" target="_blank">Abstract</a> </li> <li>AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 [<a href="https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html" rel="nofollow" target="_blank">press release</a>]. April 14, 2020.</li> <li>Chong EA et al. BTK inhibitors in cancer patients with COVID19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte). Clin Cancer Res 2020;[Published OnlineFirst]. <a href="https://clincancerres.aacrjournals.org/content/early/2020/04/28/1078-0432.CCR-20-1427" rel="nofollow" target="_blank">Abstract</a></li> <li>COVID-19 and CLL: Frequently Asked Questions. <a href="https://www.hematology.org/covid-19/covid-19-and-cll" rel="nofollow" target="_blank">Hematology.org</a>. May 6, 2020;Version 1.3.</li> <li>Mehta P et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229);1033-4. <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/fulltext" rel="nofollow" target="_blank">Correspondence</a></li> <li>Koffman B et al. Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol 2020;[Epub ahead of print]. <a href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.25851" rel="nofollow" target="_blank">Correspondence</a></li> <li>Treon ST et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood 2020;135(21):1912–5. <a href="https://ashpublications.org/blood/article/135/21/1912/454437/The-BTK-inhibitor-ibrutinib-may-protect-against" rel="nofollow" target="_blank">Full text</a></li></ul>

Dr Jeff Sharman Comments on the Use of BTK Inhibitors as Treatment for Patients with  SARS-CoV-2

We begin this episode by responding to listener feedback from episode 1.61's discussion of clinic appointment time and rates of cancer screening. We also tackle listeners' outcry over our take-down of BILCAP (spoiler alert: BILCAP is still a null trial) and how outcry like this highlights the need to train clinicians to think probabilistically. From there, we move on to discussing the recent paper by Myung Sun Kim in JAMA Network Open on waterfall plots and how they are a visual distortion of response rate. We end the episode with an interview with Dr. Jeff Sharman of Willamette Valley Cancer Institute in Eugene, Oregon on community oncology, enrolling patients in clinical trials, expertise of academia, and using real-world evidence.Waterfall plots: doi.org/10.1001/jamanetworkopen.2019.3981Back us on Patreon! www.patreon.com/plenarysession

We begin this episode by responding to listener feedback from episode 1.61's discussion of clinic appointment time and rates of cancer screening. We also tackle listeners' outcry over our take-down of BILCAP (spoiler alert: BILCAP is still a null trial) and how outcry like this highlights the need to train clinicians to think probabilistically. From there, we move on to discussing the recent paper by Myung Sun Kim in JAMA Network Open on waterfall plots and how they are a visual distortion of response rate. We end the episode with an interview with Dr. Jeff Sharman of Willamette Valley Cancer Institute in Eugene, Oregon on community oncology, enrolling patients in clinical trials, expertise of academia, and using real-world evidence. Waterfall plots: <a href="http://doi.org/10.1001/jamanetworkopen.2019.3981" rel="nofollow" target="_blank">doi.org/10.1001/jamanetworkopen.2019.3981</a> Back us on Patreon! <a href="http://www.patreon.com/plenarysession" rel="nofollow" target="_blank">www.patreon.com/plenarysession</a>

1.62 Rates of Cancer Screening, BILCAP Outcry, Waterfall Plots and Response Rate, & Dr. Jeff Sharman

Interview with Jeff Sharman, MD conducted by Neil Love, MD. Produced by Research To Practice.

CaCU1 2016 | Interview with Jeff Sharman, MD

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Jeff Sharman, MD conducted by Neil Love, MD. Produced by Research To Practice.

Jeff Sharman

Weekly hand curated podcast episodes for learning